ArdorComm Media Group

Wednesday, July 2, 2025 12:25 AM

Post-Merger Integration

Majority of HR Teams Unready for 2025 M&A Surge, Says WTW Report

With merger and acquisition (M&A) activity expected to rebound strongly in late 2025, a new survey by WTW highlights growing concerns around HR preparedness in navigating complex deal landscapes. According to the Asia-Pacific-focused report, 54% of organisations expect a rise in M&A activity this year, despite a sluggish start, while only 19% anticipate a decline — signalling a potential late-year acceleration driven by pent-up market momentum. However, the report reveals a significant preparedness gap, as 65% of HR professionals admit they feel underprepared to handle the anticipated wave of deals. Among the top challenges cited are conducting thorough HR due diligence (HRDD), pinpointing critical talent, and aligning workplace cultures post-merger. A notable 78% of companies rank the identification of specialised, non-executive talent as their foremost HRDD priority — a concern that overshadows even leadership retention. In fact, 50% of respondents consider retaining this non-executive workforce as the most vital integration success factor, outpacing the emphasis on executive-level continuity by 21 percentage points. Cultural integration remains another major obstacle. Around 74% of companies outside the US and 54% of those within the US consider cultural alignment the most challenging aspect of M&A, surpassing concerns around technological and operational resources. Looking to the future, HR leaders are increasingly acknowledging the role of emerging technologies. About 65% believe Generative AI will influence M&A processes within the next two years. Yet, widespread adoption remains cautious, with many citing limited practical applications beyond legal assessments and internal communications. The findings underscore the importance of embedding HR early in M&A strategy — particularly as companies use acquisitions to gain access to niche digital and AI talent. Strengthening HR capabilities through foresight and investment could be crucial in preserving long-term deal value amid intensifying talent competition. Source: Economic Times   

Majority of HR Teams Unready for 2025 M&A Surge, Says WTW Report Read More »

McKesson to Acquire Controlling Interest in Florida Cancer Specialists’ Management Services for $2.49 Billion

McKesson Corp. has announced its agreement to acquire a controlling stake in Community Oncology Revitalization Enterprise Ventures LLC (Core Ventures) for $2.49 billion in cash. Core Ventures, a business and administrative services organization established by Florida Cancer Specialists & Research Institute (FCS), supports nearly 100 FCS clinics across Florida. The transaction will give McKesson approximately 70% ownership, with FCS physicians retaining a minority interest. Core Ventures offers operational and advisory services that align practice locations, ancillary services, and patient care across FCS. The acquisition will integrate Core Ventures into McKesson’s Oncology platform, with financials reported under the US Pharmaceutical segment. FCS, which operates with more than 250 physicians and 280 advanced practice providers, will remain independently owned but will join McKesson’s US Oncology Network, enhancing community-based cancer care. “This acquisition strengthens our ability to deliver advanced treatments and enhance care experiences while reducing costs,” said Brian Tyler, CEO of McKesson. “Our collaboration with FCS and Core Ventures aligns with our commitment to improving patient outcomes and expanding access to quality care.” FCS CEO Nathan Walcker echoed the sentiment: “This partnership with McKesson and joining The US Oncology Network is a significant step for FCS. It enhances our mission to deliver patient-centered cancer care and bring cutting-edge medicine into communities across Florida.” The deal is subject to regulatory clearances and standard closing conditions. Source: hcinnovationgroup

McKesson to Acquire Controlling Interest in Florida Cancer Specialists’ Management Services for $2.49 Billion Read More »